SCHEMBL24315980

SCHEMBL24315980

CN1CC(C)(c2ccc3c4c(ccnc24)N(C2CCC(=O)NC2=O)C3=O)C1

nearest known ligand 0.45

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 19/20 0.45
DDB1 Q16531 12/20 0.45
IKZF3 Q9UKT9 2/20 0.45
ALDH1A1 P00352 1/20 0.45
CHRM2 P08172 1/20 0.45
OPRM1 P35372 1/20 0.45
CYP1A2 P05177 1/20 0.45
TSHR P16473 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
TNF P01375 1/20 0.39
IL1B P01584 1/20 0.39
TBXA2R P21731 1/20 0.39
IKZF1 Q13422 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24315747 0.91 CRBN (0.47) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL24315833 0.90 CRBN (0.44) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL24315977 0.87 DDB1 (0.43) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL24315815 0.84 CRBN (0.47) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL24316231 0.82 CRBN (0.49) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL24315872 0.82 CRBN (0.56) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL24315768 0.82 CRBN (0.47) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL24317674 0.81 CRBN (0.54) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL24315801 0.81 CRBN (0.53) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL24315722 0.81 CRBN (0.53) CRBNDDB1IKZF3ALDH1A1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022081925-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed
US-9585884-B2 Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 AUSPEX PHARMACEUTICALS, INC. (US) 2017-03-07 US disclosed